Drug Profile
AZ 6197
Alternative Names: AZ6197; Compound 35 - AstraZenecaLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
- 27 Oct 2017 Early research in Cancer in United Kingdom (Parenteral)
- 26 Oct 2017 Preliminary pharmacodynamic data from early research and development in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)